AKT1 and neuroblastoma: The potential efficacy of inhibiting the PI3K/Akt/mTOR pathway has been observed in NB preclinical studies [38,44,45,46], and several strategies have been developed to interfere with distinct components of this pathway, showing promises for molecular targeted therapies in advanced stage NB tumors [42,45,47].